122 related articles for article (PubMed ID: 21353137)
21. The use of sunitinib in renal cell carcinoma: where are we now?
Czarnecka AM; Szczylik C; Rini B
Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
[TBL] [Abstract][Full Text] [Related]
22. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D
Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995
[TBL] [Abstract][Full Text] [Related]
23. Sunitinib rechallenge in metastatic renal cell carcinoma patients.
Zama IN; Hutson TE; Elson P; Cleary JM; Choueiri TK; Heng DY; Ramaiya N; Michaelson MD; Garcia JA; Knox JJ; Escudier B; Rini BI
Cancer; 2010 Dec; 116(23):5400-6. PubMed ID: 21105118
[TBL] [Abstract][Full Text] [Related]
24. Severe neurological symptoms in a patient with advanced renal cell carcinoma treated with sunitinib.
Duchnowska R; Miciuk B; Bodnar L; Waśniewski L; Szczylik C
J Oncol Pharm Pract; 2013 Jun; 19(2):186-9. PubMed ID: 23037634
[TBL] [Abstract][Full Text] [Related]
25. Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation.
Teo YL; Chong XJ; Chue XP; Chau NM; Tan MH; Kanesvaran R; Wee HL; Ho HK; Chan A
Cancer Chemother Pharmacol; 2014 Feb; 73(2):381-8. PubMed ID: 24306119
[TBL] [Abstract][Full Text] [Related]
26. Skin depigmentation induced by sunitinib treatment of renal cell carcinoma.
Al Enazi MM; Kadry R; Mitwali H
J Am Acad Dermatol; 2009 Nov; 61(5):905-6. PubMed ID: 19836653
[No Abstract] [Full Text] [Related]
27. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma.
Tsai KY; Yang CH; Kuo TT; Hong HS; Chang JW
J Clin Oncol; 2006 Dec; 24(36):5786-8. PubMed ID: 17179114
[No Abstract] [Full Text] [Related]
28. Rho kinase inhibition mitigates sunitinib-induced rise in arterial pressure and renal vascular resistance but not increased renal sodium reabsorption.
Grisk O; Koenen A; Meissner T; Donner A; Braun D; Steinbach A; Glöckl G; Zimmermann U; Evert K; Evert M; Katsari E; Löhn M; Plettenburg O; Rettig R
J Hypertens; 2014 Nov; 32(11):2199-210; discussion 2110. PubMed ID: 25275248
[TBL] [Abstract][Full Text] [Related]
29. Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers.
Castellano D; Ravaud A; Schmidinger M; De Velasco G; Vazquez F
Cancer Treat Rev; 2013 May; 39(3):230-40. PubMed ID: 22647546
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
Li XS; Wu X; Zhao PJ; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; Wang G; He ZS; Zhou LQ; Jin J
Chin Med J (Engl); 2011 Sep; 124(18):2920-4. PubMed ID: 22040503
[TBL] [Abstract][Full Text] [Related]
31. Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience.
Zhou A
Asia Pac J Clin Oncol; 2012 Jun; 8(2):132-44. PubMed ID: 22524572
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases.
Makino K; Yoda K; Tomoishi J; Kume H
BMC Res Notes; 2014 Dec; 7():872. PubMed ID: 25471941
[TBL] [Abstract][Full Text] [Related]
33. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
34. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
[TBL] [Abstract][Full Text] [Related]
35. Acute cardiac failure after sunitinib.
Machiels JP; Bletard N; Pirenne P; Jacquet L; Bonbled F; Duck L
Ann Oncol; 2008 Mar; 19(3):597-9. PubMed ID: 18272908
[No Abstract] [Full Text] [Related]
36. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
Kondo T
Nihon Jinzo Gakkai Shi; 2012; 54(5):574-80. PubMed ID: 22991835
[No Abstract] [Full Text] [Related]
37. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma.
Ohzeki T; Fukasawa S; Komaru A; Namekawa T; Sato Y; Takagi K; Kobayashi M; Uemura H; Ichikawa T; Ueda T
Int J Urol; 2014 Oct; 21(10):1065-8. PubMed ID: 24930736
[TBL] [Abstract][Full Text] [Related]
39. Tolerability of first-line therapy for metastatic renal cell carcinoma.
Porta C; Szczylik C
Cancer Treat Rev; 2009 May; 35(3):297-307. PubMed ID: 19249157
[TBL] [Abstract][Full Text] [Related]
40. Response to 'Thyrotoxicosis during sunitinib treatment for renal cell carcinoma' by Grossmann et al.
Daniels GH
Clin Endocrinol (Oxf); 2009 Sep; 71(3):455. PubMed ID: 19138312
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
